# Uterovaginal Plexus Block With Articaine for Intrauterine Device Placement Patients Who Are Indicated for the Use of Copper IUD as a Contraceptive Method Will be Invited to Participate in This Research.

> **NCT05252117** · PHASE4 · UNKNOWN · sponsor: **Universidade do Vale do Sapucai** · enrollment: 240 (estimated)

## Conditions studied

- Contraception
- IUD
- Anesthesia, Local

## Interventions

- **DRUG:** Articaine Hydrochloride 40 MG/ML
- **DRUG:** Mepivacaine

## Key facts

- **NCT ID:** NCT05252117
- **Lead sponsor:** Universidade do Vale do Sapucai
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-02-01
- **Primary completion:** 2022-04-30
- **Final completion:** 2022-12-10
- **Target enrollment:** 240 (ESTIMATED)
- **Last updated:** 2022-02-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05252117

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05252117, "Uterovaginal Plexus Block With Articaine for Intrauterine Device Placement Patients Who Are Indicated for the Use of Copper IUD as a Contraceptive Method Will be Invited to Participate in This Research.". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT05252117. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*